武汉科斯坦生物科技有限公司
服务热线:15926423062
产品展厅
NVP-BEZ235
  • 品牌:Chemstan
  • 产地:中国
  • 货号:LC-01
  • cas:915019-65-7
  • 价格: ¥500/支
  • 发布日期: 2019-11-26
  • 更新日期: 2025-09-26
产品详请
产地 中国
品牌 Chemstan
货号 LC-01
用途 中间体
包装规格 20mg
纯度 98%%
CAS编号 915019-65-7
是否进口

联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体,主打中药对照品/标准品/天然植物有效单体,小分子化合物库,药物杂质。所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务。


Fields of Application : 
BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively, and also inhibits ATR with IC50 of 21 nM.

CAS Number:915019-65-7
Purity:

>98%

Molecular Weight:469.55
Molecular Formula:C30H23N5O

Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)

Synonyms:BEZ235
Chemical Name:2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile
Storage:2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO

Note: Products for research use only, not for human use

Description:
Description of BEZ235: BEZ235 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BEZ235 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). For the detailed information about the solubility of NVP-BEZ235 in water, the solubility of NVP-BEZ235 in DMSO, the solubility of NVP-BEZ235 in PBS buffer, the animal experiment(test) of NVP-BEZ235,the in vivo,in vitro and clinical trial test of NVP-BEZ235,the cell experiment(test) of NVP-BEZ235,the IC50, EC50 and Affinity of NVP-BEZ235.

References: 
CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5


联系方式
手机:15926423062
手机访问官网